Sector revisions Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 16/12/2025 GMT			5-day change	1st Jan Change
391.17 ^USD	-0.08%		-5.79%	+66.24%

12-16	Alnylam announces Health Canada approval of Amvuttra®	RE
12-13	Bitcoin hoarding company Strategy remains in Nasdaq 100	RE

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	ALNYLAM PHARMACEUTICALS, INC.							24
	ELI LILLY AND COMPANY							27
	JOHNSON & JOHNSON							24
	ABBVIE INC.							28
	ROCHE HOLDING AG							18
	ASTRAZENECA PLC							19
	NOVARTIS AG							19
	MERCK & CO., INC.							26
	NOVO NORDISK A/S							20
	AMGEN INC.							27
	PFIZER INC.							24
	GILEAD SCIENCES, INC.							26
	VERTEX PHARMACEUTICALS INCORPORATED							25
	SANOFI							21
	BRISTOL-MYERS SQUIBB COMPANY							22
	GSK PLC							18
	CHUGAI PHARMACEUTICAL CO., LTD.							14
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							18
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							14
	Average							22
	Weighted average by Cap.							23